Status:
WITHDRAWN
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Lead Sponsor:
Sadat City University
Conditions:
Schizophrenia
Dyslipidemias
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-con...
Eligibility Criteria
Inclusion
- Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of Positive and Negative Syndrome Scale (PANSS)≤60.
Exclusion
- liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus
Key Trial Info
Start Date :
February 16 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04761861
Start Date
February 16 2021
End Date
December 31 2025
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy
Shibīn al Kawm, Menoufia, Egypt, 13829